DGPPN 2018 Programm

POSTERPRÄSENTATIONEN 221 MITTWOCH DONNERSTAG FREITAG SAMSTAG 005 Esketamine nasal spray combined with an oral antidepressant for relapse prevention in treatment-resistant depression: results of a double-blind, randomized withdrawal, multicenter study (SUSTAIN-1) Adam Janik, San Diego (USA) Ella Daly, Madhukar Trivedi, Honglan Li, Yun Zhang, Xiang Li, Rosanne Lane, Pilar Lim, Anna Duca, David Hough, Michael E. Thase, John M. Zajecka, Andrew Winokur, Ilona Divacka, Andrea Fagiolini, Wieslaw J. Cubala, Istvan Bitter, Pierre Blier, Richard C. Shelton, Patricio Molero, Husseini Manji, Wayne C. Drevets, Jaskaran B. Singh 006 Switching strategies for vortioxetine in the PREDDICT Study Bernhard T. Baune, Adelaide (Australien) Natalie Mills, Natalie Aboustate, Celia Fourier 007 Effect of carbamazepine on liver functionality Muhammed Touray, Kanifing (Gambia) 008 Optimization of pharmacological treatment in hospitalized psychiatric patients (OSA-PSY) Gudrun Hefner, Friedrichsdorf Martina Hahn, Sibylle C. Roll, Christoph Hiemke, Ansgar Klimke 009 Antidepressants vs. antipsychotics in the treatment of patients with high- risk for psychosis Laura von Hardenberg, Berlin Christoph U. Correll, Britta Galling 010 The impact of second-generation antipsychotic medication side-effects on functioning from a schizophrenia patient perspective: a cross-sectional, obser- vational, patient centered, web survey study Catherina Weiss, Princeton (USA) Laëtitia Bouérat Duvold, William R. Lenderking, Owen Cooper, Huda Shalhoub, Leah Kleinman, Randell Bender, Ann Hartry, Mallik Greene, Stine Rasmussen Meehan, Rajiv Tandon 011 Comparative efficacy and acceptabil- ity of antipsychotic drugs for the acute treatment of schizophrenia: a systematic review and network meta-analysis Maximilian Huhn, München Natalie Luise Peter, Johannes Schneider- Thoma, Marc Krause, Thomas Arndt, Stefan Leucht Englischsprachige Veranstaltung